DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Emcure Pharmaceuticals Q2 FY27 Earnings Call Date Announced

Kalkine India 4 hrs ago·14 Oct 2026, 11:21 am

Emcure Pharmaceuticals L

Emcure Pharmaceuticals has announced the schedule for its Q2 FY27 earnings call. The company will hold a conference call to discuss its financial performance for the quarter ended September 30, 2026. Investors can expect details on revenue, profit, and operational metrics during this session.

This announcement is significant for shareholders as it provides a structured timeline to review the company's recent business progress. By listening to the call, investors can gain insights into management's outlook and strategy, which helps in assessing the stock's future performance.

Investors should watch for commentary on sales growth, cost control measures, and any guidance provided by the company regarding upcoming quarters. Keeping an eye on these factors will be crucial for understanding the stock's trajectory.